Literature DB >> 22744914

Gastroenteric neuroendocrine neoplasms classification: comparison of prognostic models.

Anna Dolcetta-Capuzzo1, Valentina Villa, Luca Albarello, Giulia M Franchi, Marco Gemma, Marina Scavini, Saverio Di Palo, Elena Orsenigo, Emanuele Bosi, Claudio Doglioni, Marco F Manzoni.   

Abstract

BACKGROUND: Gastroenteric neuroendocrine neoplasms (GE-NENs) display highly variable clinical behavior. In an attempt to assess a better prognostic description, in 2010, the World Health Organization (WHO) updated its previous classification, and the European Neuroendocrine Tumors Society (ENETS) proposed a new grading and TNM-based staging system. In the current study, the authors evaluated the prognostic significance of these models and compared their efficacy in describing patients' long-term survival to assess the best prognostic model currently available for clinicians.
METHODS: The study cohort was composed of 145 patients with extrapancreatic GE-NEN who were observed from 1986 to 2008 at a single center and were classified according to the WHO and ENETS classifications. Survival evaluations were performed using Kaplan-Meyer analyses on 131 patients. Only deaths from neoplasia were considered. A P value < .05 was considered significant. Prognostic efficacy was assessed by determining the Harrell concordance index (c-index).
RESULTS: Both the 2010 WHO and the ENETS classification were able to efficiently divide patients into classes with different prognoses. According to the model comparison, the ENETS TNM-based staging system appeared to be the strongest. All combined models were effective prognostic predictors, but the model that included the 2010 WHO classification plus ENETS staging had a higher c-index.
CONCLUSIONS: Both the 2010 WHO classification and the ENETS staging system are valid instruments for GE-NENs prognostic assessment, with TNM-based stage appearing to be the best available choice for clinicians, both alone and in association with other classifications.
Copyright © 2012 American Cancer Society.

Entities:  

Mesh:

Year:  2012        PMID: 22744914     DOI: 10.1002/cncr.27716

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  Cytological Ki-67 in pancreatic endocrine tumors: a new "must"?

Authors:  Giulia Franchi; Marco F Manzoni
Journal:  Gland Surg       Date:  2014-11

2.  Impact of clinical tumor-node-metastasis staging on survival in gastric carcinoma patients receiving surgery.

Authors:  Etsuro Bando; Rie Makuuchi; Masanori Tokunaga; Yutaka Tanizawa; Taiichi Kawamura; Masanori Terashima
Journal:  Gastric Cancer       Date:  2016-09-01       Impact factor: 7.370

Review 3.  Novel PET tracers: added value for endocrine disorders.

Authors:  Sébastien Bergeret; Judith Charbit; Catherine Ansquer; Géraldine Bera; Philippe Chanson; Charlotte Lussey-Lepoutre
Journal:  Endocrine       Date:  2019-03-14       Impact factor: 3.633

4.  Clinical Features and Long-Term Survival of Metastatic Hepatic Neuroendocrine Neoplasms Secondary to Gastroenteropancreatic Site: An Analysis by Applying the Grading Classification.

Authors:  Min Yang; Lin Zeng; Sheng-Zhong Hou; Neng-Wen Ke; Bo-le Tian; Xu-Bao Liu; Bo Xiang; Yi Zhang
Journal:  J Oncol       Date:  2020-09-15       Impact factor: 4.375

5.  The Added Prognostic Value of Preoperative Dynamic Contrast-Enhanced MRI Histogram Analysis in Patients with Glioblastoma: Analysis of Overall and Progression-Free Survival.

Authors:  Y S Choi; D W Kim; S-K Lee; J H Chang; S-G Kang; E H Kim; S H Kim; T H Rim; S S Ahn
Journal:  AJNR Am J Neuroradiol       Date:  2015-09-03       Impact factor: 3.825

Review 6.  Place of surgical resection in the treatment strategy of gastrointestinal neuroendocrine tumors.

Authors:  Sébastien Gaujoux; Alain Sauvanet; Jacques Belghiti
Journal:  Target Oncol       Date:  2012-08-25       Impact factor: 4.493

7.  The ENETS/WHO grading system for neuroendocrine neoplasms of the gastroenteropancreatic system: a review of the current state, limitations and proposals for modifications.

Authors:  Marcela S Cavalcanti; Mithat Gönen; David S Klimstra
Journal:  Int J Endocr Oncol       Date:  2016-07-14

Review 8.  18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.

Authors:  Sona Balogova; Jean-Noël Talbot; Valérie Nataf; Laure Michaud; Virginie Huchet; Khaldoun Kerrou; Françoise Montravers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-16       Impact factor: 9.236

9.  Comparison of the prognostic values of the 2010 WHO classification, AJCC 7th edition, and ENETS classification of gastric neuroendocrine tumors.

Authors:  Beom Su Kim; Young Soo Park; Jeong Hwan Yook; Byung-Sik Kim
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

10.  Differing Clinical Courses and Prognoses in Patients With Gastric Neuroendocrine Tumors Based on the 2010-WHO Classification Scheme.

Authors:  Beom Su Kim; Young Soo Park; Jeong Hwan Yook; Sung Tae Oh; Byung-Sik Kim
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.